登陆
当前位置: 首页 >> 检索结果

结果排序

文献格式

出版时间

出版类型

出版语言
共有 11008 条符合本次的查询结果， 用时 1.5894822 秒

61. In HFrEF, adding digitoxin to standard care reduced a composite of death or first worsening HF hospitalization at a median 36 mo.

作者: Salil Kumar.;Anita Deswal.; .
来源: Ann Intern Med. 2026年179卷1期JC8页
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

62. GLP-1RAs increase risk for cholelithiasis and GERD but not other GI or biliary adverse events vs. placebo.

作者: Kelsey L Anderson.;Joseph D Feuerstein.; .
来源: Ann Intern Med. 2026年179卷1期JC11页
GIM/FP/GP: [Formula: see text] Endocrinology: [Formula: see text] Gastroenterology: [Formula: see text].

63. Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists on Diabetic Foot Disease : An Emulated Target Trial.

作者: Frederik P B Kristensen.;Diana H Christensen.;Brian C Callaghan.;Jens S Nielsen.;Henning Andersen.;Henrik T Sørensen.;Reimar W Thomsen.
来源: Ann Intern Med. 2026年179卷3期340-352页
The effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2is) on diabetic foot disease have been mixed in prior trials of SGLT-2is compared with placebo. The comparative risk for diabetic foot disease with SGLT-2is compared with glucagon-like peptide-1 receptor agonists (GLP-1RAs) is unknown.

64. In adults at high risk for ventricular arrhythmia, treatment to increase potassium to high-normal levels improved a composite outcome.

作者: Mohammed Ruzieh.; .
来源: Ann Intern Med. 2026年179卷1期JC7页
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

65. In adults hospitalized with acute HF, predischarge influenza vaccination reduced a composite of mortality or readmission at 1 y.

作者: Juan M Teran-Plasencia.;Andre C Kalil.; .
来源: Ann Intern Med. 2026年179卷1期JC2页
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Infectious Disease: [Formula: see text].

66. In older adults, high- vs. standard-dose influenza vaccine reduced hospitalization for influenza or pneumonia.

作者: Steven Y C Tong.;Katherine B Gibney.; .
来源: Ann Intern Med. 2026年179卷1期JC3页
GIM/FP/GP: [Formula: see text] Public Health: [Formula: see text].

67. In symptomatic AF, nurse-led pre-ablation lifestyle treatment reduced repeat ablations or cardioversions at 1 y.

作者: Panteleimon E Papakonstantinou.;Gregory Y H Lip.; .
来源: Ann Intern Med. 2026年179卷1期JC6页
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

68. In provoked VTE with ≥1 enduring risk factor, extending anticoagulation with apixaban reduced symptomatic recurrent VTE at 12 mo.

作者: Andrew Dunn.; .
来源: Ann Intern Med. 2026年179卷1期JC10页
GIM/FP/GP: [Formula: see text] Hematology: [Formula: see text].

69. In older adults, RSV prefusion F vaccine reduced hospitalization for RSV-related respiratory tract disease vs. no vaccine.

作者: Henry S Sacks.; .
来源: Ann Intern Med. 2026年179卷1期JC4页
GIM/FP/GP: [Formula: see text] Geriatrics: [Formula: see text] Infectious Disease: [Formula: see text] Pulmonology: [Formula: see text].

70. In hypercholesterolemia, adding inclisiran to individually optimized lipid-lowering therapy improved LDL-C levels at 90 d.

作者: Tess Allan.;L Kristin Newby.; .
来源: Ann Intern Med. 2026年179卷1期JC9页
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

71. In older adults with impaired physical performance after MI, multidomain rehabilitation reduced CV death or CV hospitalization at 1 y.

作者: Ravishankar Ramaswamy.; .
来源: Ann Intern Med. 2026年179卷1期JC5页
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Geriatrics: [Formula: see text].

72. Effectiveness and Safety of Statins in Type 2 Diabetes According to Baseline Cardiovascular Risk : A Target Trial Emulation Study.

作者: Vincent Ka Chun Yan.;Joseph Edgar Blais.;John-Michael Gamble.;Esther Wai Yin Chan.;Ian Chi Kei Wong.;Eric Yuk Fai Wan.
来源: Ann Intern Med. 2026年179卷2期157-167页
Whether statins benefit patients with type 2 diabetes mellitus (T2DM) with low predicted 10-year cardiovascular risk is uncertain.

73. 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for the Primary Care Management of Chronic Kidney Disease.

作者: Amy R Schwartz.;Jonathan Sosnov.;Jonathan Brown.;Cynthia Delgado.;Linda Fried.;Manjula Kurella Tamura.;John W Morrison.;Sankar D Navaneethan.;Paul M Palevsky.;Diane Rybacki.;James Sall.;Sunil Verma.;Maura Watson.;Jesse Wickham.;Mai Nguyen.
来源: Ann Intern Med. 2026年179卷3期411-424页
Management of chronic kidney disease (CKD) has been rapidly evolving, now involving many interventions that can be managed in the primary care setting. In April 2025, leadership within the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) approved a joint clinical practice guideline (CPG) for the primary care management of CKD. This synopsis reviews the 2025 recommendations related to diagnosis, assessment, and management of CKD.

74. Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.

作者: Amy E Colson.;Gordon E Crofoot.;Peter J Ruane.;Moti N Ramgopal.;Alexandra W Dretler.;Ronald G Nahass.;Gary I Sinclair.;Mezgebe Berhe.;Afsoon Roberts.;Shauna Applin.;Cynthia Brinson.;Dushyantha Jayaweera.;Kimberly A Workowski.;Fadi Shihadeh.;Shan-Yu Liu.;Stephanie Klopfer.;Cyril Llamoso.;Sharline Madera.;Hadas Dvory-Sobol.;Martin S Rhee.;Elizabeth G Rhee.;Jared M Baeten.;Joseph J Eron.
来源: Ann Intern Med. 2026年179卷2期168-176页
Once-weekly oral islatravir plus lenacapavir (ISL+LEN) has the potential to address adherence challenges with daily HIV-1 treatment.

75. Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.

作者: Roger Chou.;Rongwei Fu.;Azrah Y Ahmed.;Benjamin J Morasco.
来源: Ann Intern Med. 2026年179卷2期230-241页
Benefits and harms of cannabinoids for chronic pain are uncertain.

76. Effect of Interventions Aimed at Reducing or Modifying Saturated Fat Intake on Cholesterol, Mortality, and Major Cardiovascular Events : A Risk Stratified Systematic Review of Randomized Trials.

作者: Jeremy P Steen.;Kevin C Klatt.;Yaping Chang.;Gordon H Guyatt.;Hongfei Zhu.;Mateusz J Swierz.;Dawid Storman.;Mingyao Sun.;Yunli Zhao.;Long Ge.;Lehana Thabane.;Nirjhar R Ghosh.;Giorgio Karam.;Pablo Alonso-Coello.;Malgorzata M Bala.;Bradley C Johnston.
来源: Ann Intern Med. 2026年179卷2期242-255页
Debates about optimal saturated fat advice continue.

77. Efficacy and Safety of Bisphosphonates for Complex Regional Pain Syndrome : A Systematic Review and Meta-analysis.

作者: Michael C Ferraro.;Neil E O'Connell.;Andreas Goebel.;Ruaraidh Hill.;Ffion Curtis.;Jack Wilkinson.;Jacqueline R Center.;Sylvia M Gustin.;Aidan G Cashin.;James H McAuley.
来源: Ann Intern Med. 2026年179卷2期256-269页
Clinical guidelines recommend bisphosphonates for complex regional pain syndrome (CRPS) despite limited evidence of efficacy.

78. Diagnostic Follow-up of Positive Results on Low-Dose Computed Tomography Screening in the Medicare Population.

作者: Paul F Pinsky.;Gerard Silvestri.;Raymond Osarogiagbon.;Farhood Farjah.;Eric Miller.;Ella Kazerooni.;Lindsey Enewold.;Louise Henderson.;Danielle Durham.;Robert A Smith.;Philip Connor.;Andrew Ward.;Paul Doria-Rose.
来源: Ann Intern Med. 2026年179卷2期187-195页
Diagnostic evaluation of positive screening results for lung cancer is critically important for optimal outcomes. Data on such follow-up are limited.

79. Eligibility and Prognostic Performance of Smoking Duration-Based Versus Pack-Year-Based U.S. National Lung Cancer Screening Criteria Across Racial and Ethnic Groups.

作者: Chloe C Su.;Victoria Y Ding.;Kevin Ten Haaf.;Julie T Wu.;Neal D Freedman.;Leah M Backhus.;Ann N Leung.;Natalie S Lui.;Christopher A Haiman.;Sung-Shim Lani Park.;Joel W Neal.;Rafael Meza.;Martin C Tammemägi.;Iona Cheng.;Loïc Le Marchand.;Heather A Wakelee.;Eunji Choi.;Summer S Han.
来源: Ann Intern Med. 2026年179卷2期196-206页
The U.S. Preventive Services Task Force expanded lung cancer (LC) screening eligibility in 2021 (USPSTF-2021) by decreasing the minimum number of smoking pack-years from 30 to 20. Underrepresented minorities still experience disparities in screening eligibility.

80. How Would You Manage This Diabetic Patient With a Foot Infection? Grand Rounds Discussion From Beth Israel Deaconess Medical Center.

作者: Howard Libman.;Mary T LaSalvia.;Barry I Rosenblum.;Eileen E Reynolds.
来源: Ann Intern Med. 2025年178卷12期1785-1792页
Foot infections are the most common cause of hospitalization in patients with diabetes. They may be superficial, involving only the skin, or deep, involving the soft tissues or bone. Superficial infections are generally caused by aerobic gram-positive cocci, whereas deep infections, including osteomyelitis, tend to be polymicrobial in origin. Clinical manifestations of skin and soft tissue infections include local evidence of inflammation, but peripheral neuropathy and peripheral artery disease may mask these findings. Management is determined by the extent of infection and often includes oral or parenteral antibiotic therapy in combination with surgical debridement. In 2023, the International Working Group on the Diabetic Foot and the Infectious Diseases Society of America updated their guideline on the diagnosis and management of diabetic foot infection. The guideline includes specific recommendations regarding the use of inflammatory markers, tissue and bone culture, and imaging studies in the diagnosis of diabetic foot infection, as well as the indications for surgical debridement and hospitalization. Here, 2 experts in this field, an infectious diseases physician and a podiatrist, debate how to manage the case of a diabetic patient with foot infection. They discuss diagnostic and treatment challenges in the care of this population.
共有 11008 条符合本次的查询结果， 用时 1.5894822 秒